ABL Bio Inc
KOSDAQ:298380
Net Margin
ABL Bio Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
A
|
ABL Bio Inc
KOSDAQ:298380
|
1.6T KRW |
-166%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.4B USD |
8%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
12%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
139.3B USD |
2%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.6B USD |
-5%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
120.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
69.9B USD |
31%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
33B EUR |
38%
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ABL Bio Inc's most recent financial statements, the company has Net Margin of -166.2%.
You don't have any saved screeners yet